Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature.

@article{CostdoatChalumeau2005SafetyOH,
  title={Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature.},
  author={Nathalie Cost{\'e}doat-Chalumeau and Zahir Amoura and Du L{\^e} Thi Huong and Philippe P Lechat and Jean-charles Piette},
  journal={Autoimmunity reviews},
  year={2005},
  volume={4 2},
  pages={111-5}
}
Hydroxychloroquine (HCQ) is widely used in the treatment of systemic lupus erythematosus (SLE). Even if it is generally agreed that pregnancy per se increases disease activity in patients with SLE and that withdrawal of HCQ at the onset of pregnancy may result in exacerbation of SLE, use of HCQ during pregnancy has remained controversial for a long time. Parke was the first to propose continuation of HCQ throughout gestation. Currently, more than 250 pregnancies resulting in live births have… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

Management of Pregnant Lupus

Hanan Al-Osaimi, Suvarnaraju Yelamanchili
2017

Immunosuppressive drugs and fertility

Orphanet journal of rare diseases • 2015

Similar Papers

Loading similar papers…